Italfarmaco issues a letter to address the recent online discussions about the individuals who have passed away while being treated with Duvyzat (givinostat), confirming that they have determined the deaths are not related to treatment, and that all the relevant information has been submitted to regulatory authorities.
Community letter attached.
The post Letter from Italfarmaco about patient deaths while taking givinostat appeared first on CureDuchenne.